publication date: Dec. 22, 2010

In this issue: 

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal;

SEC Notifies ImClone It May Bring Action Against Company;

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study;

NCAB Grants Three MERIT Awards; Rimer To Leave NCI For Post At UNC;

NRSAs Renamed For Kirschstein.

Download (PDF 194KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.